SAGE - Sage Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
1,611
90,273
0
0
0
Cost of Revenue
-
-
-
-
0
Gross Profit
-
-
-
-
0
Operating Expenses
Research Development
339,314
282,107
210,277
120,756
69,357
Selling General and Administrative
263,242
201,404
62,878
39,407
25,293
Total Operating Expenses
640,848
483,511
273,155
160,163
94,650
Operating Income or Loss
-639,281
-393,238
-273,155
-160,163
-94,650
Interest Expense
-
-
-
-
-
Total Other Income/Expenses Net
18
22
-64
-35
-23
Income Before Tax
-612,933
-372,882
-270,120
-158,987
-94,495
Income Tax Expense
-
-
-
-
-
Income from Continuing Operations
-612,933
-372,882
-270,120
-158,987
-94,495
Net Income
-612,933
-372,882
-270,120
-158,987
-94,495
Net Income available to common shareholders
-612,933
-372,882
-270,120
-158,987
-94,495
Reported EPS
Basic
-
-8.08
-7.09
-4.75
-3.40
Diluted
-
-8.08
-7.09
-4.75
-3.40
Weighted average shares outstanding
Basic
-
46,121
38,114
33,493
27,778
Diluted
-
46,121
38,114
33,493
27,778
EBITDA
-
-393,238
-273,155
-160,163
-94,650